Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
11 hedge funds and large institutions have $1.52M invested in Provention Bio, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 2 closing their positions.
35% more capital invested
Capital invested by funds: $1.13M → $1.52M (+$393K)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCP
Silverleafe Capital Partners
Germantown,
Tennessee
|
+$46.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$39.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$9.41K |
| 2 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$7.75K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.3K |
| 4 |
BlackRock
New York
|
-$3.75K |
| 5 |
Morgan Stanley
New York
|
-$2.84K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $1.12M | +$1.41K | +600 | +0.1% |
|
2
Point72 Asset Management
Stamford,
Connecticut
| $131K | – | – | – |
|
3
Lido Advisors
Los Angeles,
California
| $61K | – | – | – |
|
|
4
BlackRock
New York
| $57K | -$3.75K | -1,596 | -6% |
|
|
SCP
5
Silverleafe Capital Partners
Germantown,
Tennessee
| $46K | +$46.9K | +20,000 | New |
|
|
6
Citadel Advisors
Miami,
Florida
| $39K | +$39.6K | +16,864 | New |
|
|
7
Goldman Sachs
New York
| $36K | -$9.41K | -4,008 | -20% |
|
|
AIM
8
Alambic Investment Management
Belvedere,
California
| $30K | -$7.75K | -3,300 | -20% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | -$5.3K | -2,257 | -70% |
|
|
CSS
10
Cubist Systematic Strategies
Stamford,
Connecticut
| $1K | -$2.23K | -950 | -66% |
|
|
11
Morgan Stanley
New York
| – | -$2.84K | -1,212 | -96% |
|
12
Bank of America
Charlotte,
North Carolina
| – | -$1K | -739 | Closed |
|
PRVB Hedge Fund Activity: Q1 2019 in Review
11 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q1 2019, worth a combined $1.52M — up 35% from $1.13M a quarter earlier.
Fund positioning in PRVB was balanced in Q1 2019: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 6 trimmed.
The largest buyer was Silverleafe Capital Partners, opening a new position worth an estimated $46.9K. The largest seller was Goldman Sachs, cutting an estimated $9.41K.
- 11 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $1.52M of Provention Bio, Inc. Common Stock stock for Q1 2019, up 35% quarter-over-quarter.
- 2 funds opened new Provention Bio, Inc. Common Stock positions in Q1 2019 and 2 closed out, a net change of 0 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q1 2019 was Silverleafe Capital Partners, an estimated $46.9K added.
- The largest Provention Bio, Inc. Common Stock seller in Q1 2019 was Goldman Sachs, an estimated $9.41K sold.
Based on aggregated 13F filings for Q1 2019.